Showing results (171-180 of 245) with videos related to
Sort By:
Pageof 25
Journal of Hematology & Oncology|January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trialJorge E Cortes, Gail J Roboz, Maria R Baer, et al.Cancer Cell|October 12, 2016
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerNidal E Muvarak, Khadiza Chowdhury, Limin Xia, et al.Biology|April 3, 2021
FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.Blood Advances|July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionSumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.JAMA|May 9, 2024
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical TrialElias Jabbour, Hagop M Kantarjian, Ibrahim Aldoss, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.Journal of Geriatric Oncology|November 1, 2019
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)Heidi D Klepin, Ellen Ritchie, Brittny Major-Elechi, et al.Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory MyelofibrosisJohn Mascarenhas, Rami S Komrokji, Francesca Palandri, et al.Pageof 25